Olympus Corporation (TYO:7733)
Japan · Delayed Price · Currency is JPY 1,872.50
-2.50 (-0.13%)
May 20, 2026, 3:30 PM JST
Revenue by Geography
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Japan Revenue | 103.91B | 110.53B | ||||||||||||
Japan Revenue Growth | -5.99% | -5.77% | ||||||||||||
North America Revenue | 405.49B | 413.90B | ||||||||||||
North America Revenue Growth | -2.03% | 17.84% | ||||||||||||
Europe Revenue | 281.07B | 254.62B | ||||||||||||
Europe Revenue Growth | 10.39% | 7.54% | ||||||||||||
China Revenue | 82.45B | 95.74B | ||||||||||||
China Revenue Growth | -13.88% | -9.97% | ||||||||||||
Asia and Oceania Revenue (Post-FY2019 Reporting) | 102.59B | 93.71B | ||||||||||||
Asia and Oceania Revenue (Post-FY2019 Reporting) Growth | 9.47% | 6.50% | ||||||||||||
Asia and Oceania Revenue (Pre-FY2020 Reporting) | 185.04B | 189.45B | ||||||||||||
Asia and Oceania Revenue (Pre-FY2020 Reporting) Growth | -2.33% | -2.51% | ||||||||||||
Other Countries Revenue | 35.17B | 28.84B | ||||||||||||
Other Countries Revenue Growth | 21.94% | 10.46% |
Revenue Breakdown
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Gastrointestinal Solutions Division Revenue | 697.36B | 674.04B | ||||||||||||
Gastrointestinal Solutions Division Revenue Growth | 3.46% | - | ||||||||||||
Surgical & Interventional Solutions Division Revenue | 313.11B | 322.76B | ||||||||||||
Surgical & Interventional Solutions Division Revenue Growth | -2.99% | - |
Revenue Breakdown 2
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Endoscopic Solutions Division Revenue | 636.14B | ||||||||||||
Endoscopic Solutions Division Revenue Growth | 8.44% | ||||||||||||
Therapeutic Solutions Division Revenue | 360.66B | ||||||||||||
Therapeutic Solutions Division Revenue Growth | 6.92% | ||||||||||||
Total Medical Solutions Division Revenue | 996.80B | ||||||||||||
Total Medical Solutions Division Revenue Growth | 7.89% | ||||||||||||
Other Division Revenue (Post-FY2024 Reporting) | 530.00M | ||||||||||||
Other Division Revenue (Post-FY2024 Reporting) Growth | -70.62% |
EBIT
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Gastrointestinal Solutions Division Operating Profit | 136.36B | 171.44B | ||||||||||||
Gastrointestinal Solutions Division Operating Profit Growth | -20.46% | - | ||||||||||||
Surgical & Interventional Solutions Division Operating Profit | -14.99B | 15.27B |
EBIT 2
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Endoscopic Solutions Division Operating Profit | 141.40B | ||||||||||||
Endoscopic Solutions Division Operating Profit Growth | 35.07% | ||||||||||||
Therapeutic Solutions Division Operating Profit | 61.45B | ||||||||||||
Total Medical Solutions Division Operating Profit | 202.85B | ||||||||||||
Total Medical Solutions Division Operating Profit Growth | 110.82% | ||||||||||||
Other Division Operating Profit (Post-FY2024 Reporting) | -473.00M | ||||||||||||
Eliminations from Division Operating Profit | -39.92B |
Key Performance Indicators
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment | - | 3.00% | ||||||||||||
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | - | 5.00% | ||||||||||||
ESD - Medical Service Revenue Growth Rate After FX Adjustment | - | 5.00% | ||||||||||||
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment | - | 4.00% | ||||||||||||
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | - | 2.00% | ||||||||||||
TSD - Urology Revenue Growth Rate After FX Adjustment | - | 6.00% | ||||||||||||
TSD - Respiratory Revenue Growth Rate After FX Adjustment | - | 10.00% | ||||||||||||
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | - | -7.00% | ||||||||||||
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment | - | 3.00% | ||||||||||||
GSD - GI Endoscopy Revenue Growth Rate After FX Adjustment | 1.00% | - | ||||||||||||
GSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | 4.00% | - | ||||||||||||
GSD - Medical Service Revenue Growth Rate After FX Adjustment | 3.00% | - | ||||||||||||
Total Gastrointestinal Solutions Division Revenue Growth Rate After FX Adjustment | 2.00% | - | ||||||||||||
SIS - Respiratory Revenue Growth Rate After FX Adjustment | 1.00% | - | ||||||||||||
SIS - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | -6.00% | - | ||||||||||||
SIS - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | -15.00% | - | ||||||||||||
Total Surgical & Interventional Solutions Division Revenue Growth Rate After FX Adjustment | -4.00% | - |
Updated Mar 31, 2026. Data Source: Fiscal.ai.